---
abstract: ''
authors:
- Bald, Elizabeth
- Raber, Hanna
category: Clinical Review
clinical_significance: High
cme_credits: 0.0
doi: ''
evidence_level: ''
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36689981/
file_path: 2023/01/semaglutide-wegovy-for-the-treatment-of-obesity.md
issue: '1'
keywords:
- Diabetes Mellitus, Type 2
- Obesity
- Humans
- Glucagon-Like Peptides
- Diabetes
- Hypoglycemic Agents
last_updated: '2025-08-09'
mesh_terms:
- Humans
- Obesity
- Glucagon-Like Peptides
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
original_format: PubMed
pages: 90-91
patient_population: Adults
peer_reviewed: true
pmid: '36689981'
processed_date: '2025-08-09'
publication_date: '2023-01-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 1
source: American family physician
specialties:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Semaglutide (Wegovy) for the Treatment of Obesity.
topics:
- Diabetes Mellitus
- Endocrinology
- Family Medicine
- Metabolic Disorders
volume: '107'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '36689981'
  title: Semaglutide (Wegovy) for the Treatment of Obesity.
  authors:
  - last_name: Bald
    fore_name: Elizabeth
    initials: E
    affiliation: University of Utah College of Pharmacy, Salt Lake City, Utah.
  - last_name: Raber
    fore_name: Hanna
    initials: H
    affiliation: University of Utah College of Pharmacy, Salt Lake City, Utah.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '107'
    issue: '1'
  publication_info:
    year: '2023'
    month: '01'
    full_date: '2023-01-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Obesity
    major_topic: true
  - descriptor: Glucagon-Like Peptides
    major_topic: false
  - descriptor: Diabetes Mellitus, Type 2
    major_topic: true
  - descriptor: Hypoglycemic Agents
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '36689981'
  title: Semaglutide (Wegovy) for the Treatment of Obesity.
  authors:
  - name: Bald E
    authtype: Author
    clusterid: ''
  - name: Raber H
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 Jan
- pmid: '37233137'
  title: New Indication for Weight Loss Drug Semaglutide.
  authors:
  - name: Aschenbrenner DS
    authtype: Author
    clusterid: ''
  source: Am J Nurs
  pubdate: 2023 Jun 1
- pmid: '35536124'
  title: 'In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.'
  authors: []
  source: Med Lett Drugs Ther
  pubdate: 2022 May 16
- pmid: '36757837'
  title: 'In brief: Semaglutide (Wegovy) for weight loss in children.'
  authors: []
  source: Med Lett Drugs Ther
  pubdate: 2023 Feb 20
- pmid: '35226299'
  title: 'New practice in semaglutide on type-2 diabetes and obesity: clinical evidence
    and expectation.'
  authors:
  - name: Liu Y
    authtype: Author
    clusterid: ''
  - name: Luo X
    authtype: Author
    clusterid: ''
  source: Front Med
  pubdate: 2022 Feb
---

# Semaglutide (Wegovy) for the Treatment of Obesity.

**Authors:** Bald, Elizabeth, Raber, Hanna

**Published in:** American family physician | Vol. 107, No. 1 | 2023-01-01

**Links:** [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36689981/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Humans, Obesity, Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Hypoglycemic Agents

## Article Content

# Semaglutide (Wegovy) for the Treatment of Obesity.

**Authors:** Bald, Elizabeth, Raber, Hanna

**Published in:** American family physician | Vol. 107, No. 1 | 2023-01-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36689981/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Humans, Obesity, Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Hypoglycemic Agents

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36689981/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36689981/) (reference)

---

*Processed: 2025-08-09* | *PubMed Enhanced: 2025-07-30*
